Molecular Interaction Fields and 3D-QSAR Studies of p53-MDM2 Inhibitors Suggest Additional Features of Ligand-Target Interaction

被引:12
|
作者
Dezi, Cristina [1 ]
Carotti, Andrea [1 ]
Magnani, Matteo [2 ]
Baroni, Massimo [3 ]
Padova, Alessandro [2 ]
Cruciani, Gabriele [3 ,4 ]
Macchiarulo, Antonio [1 ]
Pellicciari, Roberto [1 ]
机构
[1] Univ Perugia, Dipartimento Chim & Tecnol Farmaco, I-06123 Perugia, Italy
[2] Siena Biotech SpA, I-53100 Siena, Italy
[3] Mol Discovery Ltd, Pinner HA55NE, Middx, England
[4] Univ Perugia, Dept Chem, Lab Chemometr & Cheminformat, I-06123 Perugia, Italy
关键词
STRUCTURE-BASED DESIGN; PROTEIN-PROTEIN INTERACTION; P53; PATHWAY; CONFORMATIONAL TRANSITIONS; MDMX INSIGHTS; BINDING; QSAR; OVEREXPRESSION; AMPLIFICATION; ANTAGONISTS;
D O I
10.1021/ci100113p
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The design and optimization of small molecule inhibitors of the murine double minute clone 2-p53 (p53-MDM) interaction has attracted a great deal of interest as a way to novel anticancer therapies. Herein we report 3D-QSAR studies of 41 small molecule inhibitors based on the use of molecular interaction fields and docking experiments as part of an approach to generating predictive models of MDM2 affinity and shedding further light on the structural elements of the ligand-target interaction. These studies have yielded predictive models explaining much of the variance of the 41 compound training set and satisfactorily predicting with 75% success an external test set of 36 compounds. Not surprisingly, and in full agreement with previous data, inspection of the 3D-QSAR coefficients reveals that the major driving force for potent inhibition is given by the hydrophobic interaction between the inhibitors and the p53 binding cleft of MDM2. More surprisingly, and challenging previous suggestions, the projection of the 3D-QSAR coefficients back onto the experimental structures of MDM2 provides an intriguing hypothesis concerning an active role played by the N-terminal region of MDM2 in ligand binding.
引用
收藏
页码:1451 / 1465
页数:15
相关论文
共 50 条
  • [21] NOVEL SMALL MOLECULE INHIBITORS OF THE P53-MDM2 /MDM4 INTERACTION FOR INDUCTION OF APOPTOSIS IN AML
    Koehler, L. M.
    Beck, B.
    Huang, H.
    Holak, T.
    Domling, A.
    Subklewe, M.
    HAEMATOLOGICA, 2012, 97 : 259 - 260
  • [22] Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode
    Gessier, Francois
    Kallen, Joerg
    Jacoby, Edgar
    Chene, Patrick
    Stachyra-Valat, Therese
    Ruetz, Stephan
    Jeay, Sebastien
    Holzer, Philipp
    Masuya, Keiichi
    Furet, Pascal
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (17) : 3621 - 3625
  • [23] Discovery of 1,2-Naphthoquinone Derivatives as Potent p53-MDM2 Interaction Inhibitors
    Jung, Myoung Eun
    Go, Areum
    Yoo, Dabin
    Chae, Jong-Hak
    Jeon, Moon-Kook
    Lim, Byungho
    Choi, Gildon
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2019, 40 (12) : 1236 - 1239
  • [24] α-Mangostin and Gambogic Acid as Potential Inhibitors of the p53-MDM2 Interaction Revealed by a Yeast Approach
    Leao, Mariana
    Gomes, Sara
    Pedraza-Chaverri, Jose
    Machado, Neuza
    Sousa, Emilia
    Pinto, Madalena
    Inga, Alberto
    Pereira, Clara
    Saraiva, Lucilia
    JOURNAL OF NATURAL PRODUCTS, 2013, 76 (04): : 774 - 778
  • [25] Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction
    Beloglazkina, Anastasia
    Zyk, Nikolai
    Majouga, Alexander
    Beloglazkina, Elena
    MOLECULES, 2020, 25 (05):
  • [26] FOLICation: Engineering approved drugs as potential p53-MDM2 interaction inhibitors for cancer therapy
    Patil, Sachin P.
    MEDICAL HYPOTHESES, 2013, 81 (06) : 1104 - 1107
  • [27] QSAR Models for isoindolinone-based p53-MDM2 Interaction Inhibitors Using Linear and Non-linear Statistical Methods
    Dong, Xiaowu
    Yan, Jingying
    Lu, Dong
    Wu, Peng
    Gao, Jiadi
    Liu, Tao
    Yang, Bo
    Hu, Yongzhou
    CHEMICAL BIOLOGY & DRUG DESIGN, 2012, 79 (05) : 691 - 702
  • [28] Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
    Zhu, Haohao
    Gao, Hui
    Ji, Yingying
    Zhou, Qin
    Du, Zhiqiang
    Tian, Lin
    Jiang, Ying
    Yao, Kun
    Zhou, Zhenhe
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [29] The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target
    Picksley, SM
    Spicer, JF
    Barnes, DM
    Lane, DP
    ACTA ONCOLOGICA, 1996, 35 (04) : 429 - 434
  • [30] Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
    Zanjirband, Maryam
    Rahgozar, Soheila
    CURRENT DRUG TARGETS, 2019, 20 (11) : 1091 - 1111